Rasio cepet brainstorm-cell.com (BCLI)

Brainstorm Cell (BCLI) relies on its proprietary NurOwn system, which creates a protected environment for therapeutic protocols through unique stem cell expansion methods. The asset's market value dynamics at 0.00 reflect current market expectations. The brand is valued by ALS patient communities for its innovative approach to developing drugs from the patient's own tissues, while the humanitarian status of the biomedicine ensures business stability regardless of global political tensions.

For the biotech sector, Brainstorm Cell (BCLI) must maintain a critical operational reserve until the FDA approves the NurOwn drug. This metric assesses the company's ability to settle short-term obligations using only cash and accounts receivable, excluding illiquid inventories. High values guarantee financial survival, although excess cash may limit the overall return on equity. The quick ratio trend on this chart reflects the business's current margin of safety.